Bottle Label 50 mg (71610 0207 30)
Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-207
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
The text is presenting data from a study about two medications, Atenolol and Losartan Potassium. It shows that the risk reduction with Losartan Potassium in terms of patient's primary endpoint was 13% and statistically significant (p=0.021). The rest of the text appears to be a timeline for the study months.*
Figure 2 (Spl Image3 Figure2)
This is a comparison of two drugs Atenolol and Losartan Potassium in terms of their adjusted risk reduction for fatal/non-fatal stroke. The study found that Losartan Potassium resulted in a 25% risk reduction compared to Atenolol. The accompanying table shows the percentage of patients who experienced fatal/non-fatal stroke over a period of 66 months in the study.*
Figure 3 (Spl Image4 Figure3)
Figure 3 shows the primary endpoint events within demographic subgroups for two medication groups - Losartan potassium and Atenolol. The primary composite stroke (fatal/non-fatal) rate, hazard ratio, and number of events are presented for each demographic subgroup, including age, gender, race, ISH (Isolated Systolic Hypertension), diabetes, and history of CVD (Cardiovascular Disease). The symbols are proportional to the sample size, and the data are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. Other subgroups, including Asian, Hispanic, Multi-race, Indian, Native American, and European, are combined into a single group.*
Figure 4 (Spl Image5 Figure4)
This is a graph comparing the effects of Losartan Potassium and a placebo in reducing the risk of an event in patients. The percentage of patients with an event is presented on the y-axis, while the timeline of the study is plotted on the x-axis in months. The risk reduction achieved with Losartan Potassium is 16.1%, and p=0.022. No further information is available from this text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
